Mantomed (Memantine Hydrochloride)

Memantine Hydrochloride is employed in the therapeutic approach to neurodegenerative conditions that involve glutamate‑mediated excitotoxicity, with its primary and approved indication being the treatment of Alzheimer’s disease in adults who have moderate to severe cognitive impairment.

• Alzheimer’s disease (moderate to severe): improves cognition, daily functioning, and overall clinical status in affected adults.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor ion channel. By binding within the channel at a site distinct from the glutamate binding site, it reduces excessive calcium influx caused by prolonged glutamate activation, thereby decreasing neuronal excitotoxicity and helping to preserve synaptic function in the brain.

Memantine is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Confusion: transient mental clouding.
• Hypertension: elevated blood pressure readings.
• Fatigue: feeling unusually tired.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring medical attention.
• Cardiac arrhythmia: irregular heart rhythm.
• Stevens‑Johnson syndrome: severe skin reaction.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Suicidal thoughts: emergence of depressive ideation.
• Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing Memantine Hydrochloride, clinicians should consider several safety aspects.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic disease: monitor liver enzymes regularly.
• History of seizures: use with caution and observe for neurologic changes.
• Concomitant use of other NMDA antagonists: avoid additive CNS effects.
• Elderly patients: start at low dose and titrate slowly.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Memantine Hydrochloride may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Co‑administration with other NMDA antagonists (e.g., ketamine, amantadine): may potentiate CNS depression.
• Strong CYP450 inhibitors (e.g., ketoconazole): can increase plasma levels.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents (e.g., diphenhydramine): may worsen cognitive side effects.
• Diuretics (e.g., furosemide): monitor electrolytes and renal function.
• Antihypertensive drugs: observe blood pressure for additive hypotensive effect.